Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion.

Machine translation Machine translation
类别 Primary study
期刊International journal of antimicrobial agents
Year 2009
連結 Pubmed, DOI
哌拉西林治疗管理的标准模式是间歇性的输液。然而，连续输注可以是有利的，因为β-内酰胺类抗生素表现出时间依赖性的抗菌活性。在以往的研究中，我们发现了一个更高的速率呼吸机相关性肺炎（VAP）持续输注，而不是美罗培南和头孢他啶的间歇输注临床治愈。因此，这一历史队列研究的目的是建立哌拉西林/他唑巴坦（PIP / TAZ）由连续和间歇输注VAP患者的治疗无肾功能衰竭给予的临床疗效。Logistic回归分析显示VAP的临床治愈的可能性更大了连续的，当负责VAP的微生物有8微克/毫升[8/9（88.9％）的最小抑菌浓度（MIC）间歇输注相比，与6/15 （40.0％），比值比（OR）= 10.79，95％可信区间（CI）1.01-588.24，P = 0.049]，或16微克/毫升[7/8（87.5％）与1/6（16.7％） OR = 22.89，95％CI为1.19-1880.78，P = 0.03]。因此，PIP / TAZ的通过连续输注给药，可考虑不是间断输注治疗VAP引起的革兰氏阴性菌时负责VAP微生物的MIC为8-16微克/毫升的患者无肾功能衰竭更有效。
This translation has been produced by an automated software. If you wish to submit your own translation, please send it to translations@epistemonikos.org
Epistemonikos ID: b465f183e546649c16827248a72c5c58604e95f9
First added on: Dec 14, 2013
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use